Biolidics Limited is a Singapore-based precision medicine medical technology company. The Company's principal activities are technology development, technology transfer, marketing, selling and distribution of biomedical technology, life and medicine science related products and services; provision of laboratory services; and investment holding. It has three segments: cancer diagnostics, infectious diseases and laboratory services. Cancer diagnostics segment develops and commercializes the ClearCell FX1 System, a fully automated CE-IVD medical device, which separate and enrich cancer cells from blood, allows users of the system to perform liquid biopsies. Infectious diseases segment develops, markets and/or distributes certified test kits with various diagnostic partners. Laboratory services segment offers a range of tests. The laboratory has a regulatory approval from Singapore’s Ministry of Health for molecular microbiology testing and PCR testing services for COVID-19 in Singapore.